UPDATE: UBS Starts Targa Resources (TRGP) at Buy; Dominant Midstream Provider
Tweet Send to a FriendGet Alerts TRGP Hot Sheet
Price: $65.86 --0%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 4 | New: 9
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 4 | New: 9
Trade TRGP Now!
(Updated - August 22, 2012 10:58 AM EDT)
UBS initiates coverage on Targa Resources (NYSE: TRGP) with a Buy. PT $57.00.
Analyst, Christopher P. Sighinolfi, said, "TRGP’s assets consist solely of its ~14.5% LP interest, 2% GP interest, and 100% ownership of the Incentive Distribution Rights (IDRs) in its MLP, Targa Resources Partners, L.P. (Nasdaq: NGLS). Accordingly, the sole goal of mgmt is the successful execution of NGLS’s growth strategy as TRGP’s 50% IDR splits provide a strong incentive to grow total MLP cash distributions."
For an analyst ratings summary and ratings history on Targa Resources click here. For more ratings news on Targa Resources click here.
Shares of Targa Resources closed at $44.18 yesterday, with a 52 week range of $26.76-$49.91.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
UBS initiates coverage on Targa Resources (NYSE: TRGP) with a Buy. PT $57.00.
Analyst, Christopher P. Sighinolfi, said, "TRGP’s assets consist solely of its ~14.5% LP interest, 2% GP interest, and 100% ownership of the Incentive Distribution Rights (IDRs) in its MLP, Targa Resources Partners, L.P. (Nasdaq: NGLS). Accordingly, the sole goal of mgmt is the successful execution of NGLS’s growth strategy as TRGP’s 50% IDR splits provide a strong incentive to grow total MLP cash distributions."
For an analyst ratings summary and ratings history on Targa Resources click here. For more ratings news on Targa Resources click here.
Shares of Targa Resources closed at $44.18 yesterday, with a 52 week range of $26.76-$49.91.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Starts Insmed (INSM) at Buy
- Maxim Group Starts Agenus (AGEN) at Buy, PT $19
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

